Additional Supporting Information may be found in the online version of this article.

ijc28073-sup-0001-suppfig1.tif449KSupporting Information Fig. S1
ijc28073-sup-0002-suppfig2.tif171KSupporting Information Fig. S2
ijc28073-sup-0003-suppfig3.tif968KSupporting Information Fig. S3
ijc28073-sup-0004-suppfig4.tif483KSupporting Information Fig. S4
ijc28073-sup-0005-suppfig5.tif235KSupporting Information Fig. S5
ijc28073-sup-0006-suppfig6.tif1174KSupporting Information Fig. S6
ijc28073-sup-0007-suppfig7.tif2095KSupporting Information Fig. S7
ijc28073-sup-0008-suppfig8.tif1125KSupporting Information Fig. S8
ijc28073-sup-0009-suppfig9.tif344KSupporting Information Fig. S9
ijc28073-sup-0010-suppfig10.tif486KSupporting Information Fig. S10
ijc28073-sup-0011-supptab1.doc31KSupplemental Table S1. CRC patients with KRAS and PIK3CA mutations.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.